Announcement PDF Nofice of Company Update Webinar 5 December 2024 – Melbourne, Australia: Neurizon Therapeufics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company advancing treatments for neurodegenerafive diseases, is pleased to announce that it will host a webinar “Shaping the future of neurodegenerafive diseases: Neurizon’s Mid-Year Update & Outlook”. The webinar, hosted by Managing Director and Chief Execufive Officer Dr. Michael Thurn, will offer valuable insights into Neurizon’s recent achievements, ongoing clinical progress, and strategic priorifies. Date & Time: Thursday, December 12, 2024 at 12 PM AEDT Register at: hftps://loghic.eventsair.com/268366/520327/Site/Register Aftendees are encouraged to submit their quesfions in advance, either during the registrafion process or by emailing enquiries@neurizon.com. A recording of the webinar will be available on Neurizon’s Investor Hub after its complefion. -ENDS- This announcement has been authorized for release by the Board of Neurizon Therapeufics Limited. For further informafion, please contact: Dr. Michael Thurn Managing Director and Chief Execufive Officer Neurizon Therapeufics Limited enquiries@neurizon.com +61 (3) 9692 7222 Catherine Strong Sodali & Co catherine.strong@sodali.com +61 (0)406 759 268 About Neurizon Therapeufics Limited Neurizon Therapeufics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerafive diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effecfive ALS treatments for pafients, while exploring NUZ-001’s potenfial for broader neurodegenerafive applicafions. Through internafional collaborafions and rigorous clinical programs, Neurizon is dedicated to creafing new horizons for pafients and families impacted by complex neural disorders. Neurizon Therapeufics Limited ABN 35 094 006 023. Level 4, 96-100 Albert Road, South Melbourne VIC 3205 Tel: +61 3 9692 7222, www.neurizon.com 1 Neurizon Investor Hub We encourage you to ufilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This plafform offers an opportunity to submit quesfions, share comments, and view video summaries of key announcements. To access Neurizon Investor Hub please scan the QR code or visit hftps://investorhub.neurizon.com Neurizon Therapeufics Limited ABN 35 094 006 023. Level 4, 96-100 Albert Road, South Melbourne VIC 3205 Tel: +61 3 9692 7222, www.neurizon.com 2